Contract research laboratories now have access to a game-changing technology: Azenta’s long-read Whole Genome Sequencing (WGS) test. Leveraging PacBio’s Revio sequencer, this test provides an unmatched level of genomic detail, making it an invaluable tool for rare disease research and clinical studies.
Superior genomic coverage for complex studies
Unlike short-read sequencing, Azenta’s WGS test excels in capturing genetic variations in repetitive and complex genomic regions. This capability is critical for identifying alterations that drive rare diseases, which are often missed by conventional methods.
Built for contract research applications
Performed in Azenta Life Sciences’ CLIA-certified and CAP-accredited lab, this test ensures consistent quality and compliance. Contract labs can rely on its precision to support drug development, clinical trials, and translational research.
Why contract labs should choose Azenta’s WGS Test:
- Comprehensive Genomic Insights: Detects complex genetic variants with high-resolution HiFi reads.
- Regulatory Compliance: Conducted in fully accredited facilities.
- Facilitates Rare Disease Studies: Enables breakthroughs in diagnostics and therapeutic development.
- Strengthens Client Deliverables: Offers clients a cutting-edge solution for genomic challenges.
- Streamlined Integration: Fits seamlessly into existing workflows for enhanced results.
Azenta’s long-read WGS test empowers contract labs to expand their capabilities in rare disease research. With its unparalleled precision and reliability, it sets a new standard in genomic testing.
This article is an AI generated summary of a published press release “Azenta Obtains Regulatory Approval for Clinical Long-Read Whole Genome Sequencing Test“
